As part of the transaction, Michael Ross, managing partner at SV Life Sciences, and Joseph Amprey, senior managing director of MedImmune Ventures, joined the NKT Therapeutics board.
NKT Therapeutics has licensed an extensive intellectual property (IP) portfolio from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital.
Robert Mashal, president and CEO of NKT Therapeutics, said: “I am very excited to lead the development of this very promising technology, whose broad potential for addressing major healthcare needs is underscored by this successful financing.”